Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 418

2.

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators.

N Engl J Med. 2005 Jul 21;353(3):238-48. Erratum in: N Engl J Med. 2005 Oct 13;353(15):1640.

3.

Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.

Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D.

Diabetes Care. 2006 Jun;29(6):1220-6.

PMID:
16731999
4.

Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease.

Wenger NK, Lewis SJ, Herrington DM, Bittner V, Welty FK; Treating to New Targets Study Steering Committee and Investigators.

Ann Intern Med. 2007 Jul 3;147(1):1-9.

PMID:
17606955
5.

Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators.

N Engl J Med. 2005 Apr 7;352(14):1425-35. Epub 2005 Mar 8.

6.

Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.

Shinozaki T, Matsuyama Y, Iimuro S, Umegaki H, Sakurai T, Araki A, Ohashi Y, Ito H; Japanese Elderly Diabetes Intervention Trial Research Group.

Geriatr Gerontol Int. 2012 Apr;12 Suppl 1:88-102. doi: 10.1111/j.1447-0594.2011.00816.x.

PMID:
22435944
7.

Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.

Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T; MIRACL Study Investigators.

Circulation. 2002 Sep 24;106(13):1690-5.

8.

The collaborative atorvastatin diabetes study: preliminary results.

Owen OG.

Int J Clin Pract. 2005 Jan;59(1):121-3.

PMID:
15707477
9.

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J.

Diabetes Care. 2005 May;28(5):1151-7.

PMID:
15855581
11.
12.

Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).

LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H; Treating to New Targets (TNT) Steering Committee and Investigators.

Am J Cardiol. 2007 Sep 1;100(5):747-52. Epub 2007 Jun 14.

PMID:
17719314
13.

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).

Neil HA, DeMicco DA, Luo D, Betteridge DJ, Colhoun HM, Durrington PN, Livingstone SJ, Fuller JH, Hitman GA; CARDS Study Investigators.

Diabetes Care. 2006 Nov;29(11):2378-84.

PMID:
17065671
14.

Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.

Krane V, Winkler K, Drechsler C, Lilienthal J, März W, Wanner C; German Diabetes and Dialysis Study Investigators.

Am J Kidney Dis. 2009 Nov;54(5):902-11. doi: 10.1053/j.ajkd.2009.06.029. Epub 2009 Sep 25.

PMID:
19781835
15.

Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.

Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, Sharma A, Bolmall C, Baliga VP.

J Indian Med Assoc. 2008 Jul;106(7):464-7.

PMID:
18975505
16.

Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).

Tikkanen MJ, Holme I, Cater NB, Szarek M, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR; Incremental DEcrease through Aggressive Lipid Lowering Investigators.

Am J Cardiol. 2009 Mar 1;103(5):577-82. doi: 10.1016/j.amjcard.2008.10.029. Epub 2009 Jan 17.

PMID:
19231315
17.
18.

Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.

Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators.

Circulation. 2004 Jul 27;110(4):386-91. Epub 2004 Jul 19.

20.

Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.

Sever PS, Poulter NR, Dahlof B, Wedel H; ASCOT Investigators.

J Hypertens. 2009 May;27(5):947-54. doi: 10.1097/HJH.0b013e328326cb1a.

PMID:
19318984

Supplemental Content

Support Center